Hemant Chaparala, MD
Urology · Decatur, GANPI 1043666365
Payments from drug & device makers
What this record shows
This record is dominated by grants: $25,000 of the $32,811 with a category attached, or 76.2%. Boston Scientific accounts for 77.2% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2021 at $25,035 and has fallen 93.2% since, to $1,711 in 2025. Among urology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $214.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$25K
- Teleflex LLC$3K
- Medtronic$2K
- Sumitomo Pharma America, Inc.$615
- Procept Biorobotics Corporation$301
- Astellas Pharma US Inc$248
- plus $1K from 24 others
What the payments were for
- Grants$25,00076%
- Travel & lodging$2,2437%
- Food & beverage$5,46817%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 6 | $25,341 |
| Teleflex LLC | 16 | $2,665 |
| Medtronic | 33 | $2,374 |
| Sumitomo Pharma America, Inc. | 33 | $615 |
| Procept Biorobotics Corporation | 4 | $301 |
| Astellas Pharma US Inc | 8 | $248 |
| Verity Pharmaceuticals Inc. | 7 | $158 |
| Coloplast | 5 | $119 |
| Tempus AI, Inc | 4 | $114 |
| Endo Pharmaceuticals Inc. | 1 | $89 |
| Bayer | 4 | $68 |
| Johnson & Johnson | 2 | $66 |
| Novartis | 3 | $59 |
| Urogen Pharma, Inc. | 2 | $51 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $50 |
| Dendreon Pharmaceuticals LLC | 1 | $47 |
| Tolmar, Inc. | 2 | $45 |
| Accord Healthcare, Inc. | 2 | $43 |
| Ferring Pharmaceuticals Inc. | 2 | $42 |
| AstraZeneca | 2 | $40 |
| Urovant Sciences Inc | 2 | $40 |
| ABC Home Medical Supply, Inc. | 2 | $40 |
| Antares Pharma, Inc. | 2 | $33 |
| Olympus America Inc. | 2 | $31 |
| Vertex | 1 | $30 |
| Convatec Inc. | 1 | $24 |
| Merck | 1 | $23 |
| Endo USA, Inc. | 1 | $21 |
| Laborie Medical Technologies Corp. | 1 | $19 |
| AbbVie | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$25,000
- UroLift$2,245
- INTERSTIM$1,719
- Barrigel$526
- AQUABEAM SYSTEM$143
- LithoVue$125
- AquaBeam Robotic System$113
- SpaceOAR VUE System - 10mL$108
How this compares
$32,811 in reported general payments places this provider in the 90th percentile of 369 urology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 48 | $706,781 |
| OrgovyxRelugolix | 49 | $125,601 |
| GemtesaVibegron | 146 | $122,566 |
| MyrbetriqMirabegron | 65 | $42,825 |
| Estradiol | 75 | $4,788 |
| Tamsulosin Hcl | 320 | $2,465 |
| Methenamine Hippurate | 12 | $1,515 |
| Testosterone Cypionate | 22 | $906 |
| Finasteride | 87 | $782 |
| Testosterone | 14 | $576 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 55 | $522 |
| Ketorolac Tromethamine | 46 | $413 |
| Cefdinir | 35 | $373 |
| Solifenacin Succinate | 13 | $268 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 12 | $218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $66 | $706,78148 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $615 | $248,167195 claims |
| Astellas Pharma US IncMyrbetriq | $248 | $42,82565 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 369 urology providers in Georgia.
Other urology in Decatur
- Daniel CanterDecatur$329K
- Michael KemperDecatur$72K
- Syed JafriDecatur$21K
- Vahan KassabianRoswell$1.6M
- Lewis KritemanRoswell$864K
- Tariq HakkyAtlanta$140K
- Sherita KingAugusta$108K
- Brittani Barrett-HarlowFayetteville$100K
- James BennettAtlanta$93K
- Anthony BarnesAtlanta$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.